Article
Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
Cancer research - 15 Dec 2014
Bai Yun, Kim Jae-Young, Watters January M, Fang Bin, Kinose Fumi, Song Lanxi, Koomen John M, Teer Jamie K, Fisher Kate, Chen Yian Ann, Rix Uwe, Haura Eric B
Abstract excerpt
DDR2 mutations occur in approximately 4% of lung squamous cell cancer (SCC) where the tyrosine kinase inhibitor dasatinib has emerged as a new therapeutic option. We found that ERK and AKT phosphorylation was weakly inhibited by dasatinib in DDR2-mutant lung SCC cells, suggesting that dasatinib inhibits survival signals distinct from other oncogenic receptor tyrosine kinases (RTK) and/or compensatory signals...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.